GlaxoSmithKline Pharmaceuticals Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GLAXO.NS | PFE | GSK | 0QYQ.IL | MRK | AZN | |
|---|---|---|---|---|---|---|
| Market cap | 423.46B | 175.50B | 102.53B | 218.56B | 370.96B | 293.14B |
| P/E (TTM) | 36.3 | 44.0 | 17.8 | 40.3 | 151.9 | 26.7 |
| Forward P/E | 31.6 | 10.6 | 10.3 | — | 16.7 | 16.7 |
| Price/book | 18.7 | 2.1 | 4.1 | 10.3 | 8.9 | 5.7 |
| Dividend yield | 2.21% | 5.59% | 3.55% | 3.81% | 2.26% | 1.69% |
| 1-year change | −3.14% | +23.90% | +4.30% | +38.91% | +75.29% | +12.81% |
| Today | −1.27% | +2.63% | +5.03% | +1.98% | +3.93% | +2.79% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All GLAXO.NS news ›GlaxoSmithKline Pharmaceuticals Sets November 3 Results Review
GlaxoSmithKline Pharmaceuticals Limited is scheduled to review financial results at a board meeting on November 3, 2026. The company’s calendar disclosure, released on October 13, identifies the financial-results review as the key agenda…
GlaxoSmithKline Pharmaceuticals reports Q2 FY27 results and key appointments
GlaxoSmithKline Pharmaceuticals announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company also informed about the appointment of a new Head of Ethics & Compliance and the approval…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- investywise.com2
- multibagg.ai1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.